Recent News

• 09.15.2025 - Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
• 07.31.2025 - OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results
• 07.31.2025 - OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results
• 07.24.2025 - OPKO Health to Report Second Quarter 2025 Financial Results on July 31
• 07.24.2025 - OPKO Health to Report Second Quarter 2025 Financial Results on July 31
• 07.08.2025 - OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
• 07.08.2025 - OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
• 06.25.2025 - OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium
• 06.25.2025 - OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium
• 06.25.2025 - OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting

Recent Filings

• 09.15.2025 - 8-K Current report
• 09.15.2025 - EX-99.1 EX-99.1
• 08.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.31.2025 - 8-K Current report
• 07.31.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.31.2025 - EX-99.1 EX-99.1
• 07.09.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors